Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q13094

UPID:
LCP2_HUMAN

ALTERNATIVE NAMES:
SH2 domain-containing leukocyte protein of 76 kDa; SLP-76 tyrosine phosphoprotein

ALTERNATIVE UPACC:
Q13094; A8KA25; Q53XV4

BACKGROUND:
The protein Lymphocyte cytosolic protein 2, with alternative names SH2 domain-containing leukocyte protein of 76 kDa and SLP-76 tyrosine phosphoprotein, is integral to T-cell antigen receptor signaling. Its function is essential for the orchestration of the immune response, enabling the communication necessary for T cells to effectively respond to antigens.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Lymphocyte cytosolic protein 2 could open doors to potential therapeutic strategies for treating Immunodeficiency 81. This disease, marked by severe immune dysfunction and recurrent infections, is caused by genetic variants in the gene encoding this protein, highlighting its significance in immune system health and disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.